National Emerging Infectious Diseases Laboratories Operations

国家新发传染病实验室运作

• 批准号: 10663821
• 负责人: Nancy Jean Sullivan
• 金额: $ 1150万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663821
• 关键词: Acceleration; Advanced Development; Animal Model; Animals; Area; Attention; Basic Science; Biology; Boston; Categories; Clinical Research; Collaborations; Communities; Comparative Study; Complement; Containment; Development; Diagnosis; Diagnostic; Diagnostic tests; Discipline; Emergency Situation; Emerging Communicable Diseases; Engineering; Environment; Environmental Health; Event; Faculty; Faculty Recruitment; Goals; Health; Human; Human Resources; Infectious Diseases Research; Information Technology; International; Investigation; Laboratories; Medical; Medical center; Methodology; Mission; Modeling; Pathogenesis; Pathogenicity; Physiological; Process; Public Health; Public Health Schools; Reporting; Research; Research Personnel; Research Support; Safety; Science; Scientist; Secure; Security; Services; Strategic Planning; Teaching Hospitals; Therapeutic; Training; Training and Education; Translational Research; United States; Universities; Vaccines; Veterinary Pathology; biodefense; biosecurity; emerging pathogen; experience; flexibility; human disease; improved; innovation; insight; interest; medical schools; microbial; new technology; next generation; operation; pandemic pathogen; pandemic potential; pathogen; pre-clinical research; prevent; programs; recruit; research and development; research facility; response; skills; tool; vaccine evaluation

Overall Abstract The National Biocontainment Laboratory (NBL) at Boston University (BU) is known as the National Emerging Infectious Diseases Laboratories (NEIDL). It is owned and operated by BU and is located on the Boston University Medical Campus (BUMC) adjacent to the BU School of Medicine, the Graduate Sciences program, the BU School of Public Health, and the affiliated teaching hospital, Boston Medical Center. The NEIDL's missions are: (1) To perform innovative basic, translational and clinical research on emerging infectious diseases in order to develop diagnostic tests, treatments and vaccines to promote the public's health; (2) To provide training in these areas of research and to support a national response in the event of a biodefense emergency; and (3) To establish a research facility with the highest attention to community and laboratory safety and security. In order to successfully achieve these missions, the NEIDL's goals are to: (1) Recruit and develop a cadre of investigators and research staff with expertise in the scientific disciplines required to investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents, including collaborations within the university, in the United States, and internationally; (2) Develop animal models for the comparative study of these pathogens, mimicking as closely as possible the human disease process, and build capacity for the creation and use of relevant animal models and innovative veterinary research support; (3) Perform translational, preclinical and clinical research in animals and humans; (4) Develop the methodologies needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents; (5) Train the next generation of research scientists and related support personnel in the requirements to perform maximum containment research in a safe and secure environment;( 6) Maintain the flexibility needed to support a national response in the event of a biodefense emergency; (7) Establish a "safety first" environment for the conduct of all activities in the Institute. Since opening for research at the BSL-4 and ABSL-4 levels in 2018, NEIDL has rapidly moved forward to recruit additional faculty whose skills and interests both expand and complement existing expertise, bring innovative new insights and methodology to expand our scientific capabilities, open up research on new pathogens. In order to advance vaccines and therapeutics, the NEIDL has expanded its Regulatory Compliance Group and practices to permit studies to be carried out under Well- Documented practices. The NEIDL focuses on and supports innovative science, led by our faculty investigators, and as a result we also continue to evolve our integrated research support services to provide support needed for BSL-4 research to better reflect and provide access to new technology and research approaches, in order to remain at the leading edge of science.

全面的 抽象的 波士顿大学（BU）的国家生物娱乐实验室（NBL）被称为国家新兴 传染病实验室（NEIDL）。它由BU拥有和运营，位于波士顿 大学医学校园（BUMC）毗邻BU医学院研究生科学课程， BU公共卫生学院和波士顿医疗中心的附属教学医院。尼德尔的 任务是：（1）对新兴传染性进行创新的基本，转化和临床研究 疾病以开发诊断测试，治疗和疫苗以促进公众的健康； （2）至 在这些研究领域提供培训，并在生物实现的情况下支持国家反应 紧急情况; （3）建立一个对社区和实验室最高关注的研究机构 安全和保障。为了成功实现这些任务，Neidl的目标是：（1）招募和 在需要专业知识的科学学科中，开发一群研究人员和研究人员 研究由A，B类和C剂引起的新兴传染病的发病机理，包括 大学内部和国际上的合作； （2）开发动物模型 这些病原体的比较研究，尽可能地模仿人类疾病过程，并建立 创建和使用相关动物模型和创新兽医研究支持的能力； （3） 对动物和人类进行翻译，临床前和临床研究； （4）开发方法 需要推进这些药物的疫苗，治疗剂和诊断的开发和测试； （5） 培训下一代研究科学家和相关支持人员的要求 在安全环境中的最大遏制研究；（6）保持所需的灵活性 在发生生物陷入紧急情况的情况下，支持国家反应； （7）建立“安全性第一”环境 为了进行研究所的所有活动。自从在BSL-4和ABSL-4级别进行研究以来 2018年，Neidl迅速发展，招募了其他教师，他们的技能和兴趣都在扩展和 补充现有的专业知识，带来创新的新见解和方法，以扩大我们的科学 功能，开放对新病原体的研究。为了推进疫苗和治疗疗法，NEIDL 扩大了其监管合规组和实践，以允许在良好的情况下进行研究 有记录的做法。 NEIDL专注于我们的教师领导的创新科学 调查人员，结果我们还继续发展我们的综合研究支持服务以提供 BSL-4研究所需的支持，以更好地反映和提供新技术和研究的访问 方法是为了保持科学的领先地位。

项目成果

Ranking the risk of animal-to-human spillover for newly discovered viruses.

• DOI: 10.1073/pnas.2002324118
• 发表时间: 2021-04-13
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1
• 作者: Grange ZL;Goldstein T;Johnson CK;Anthony S;Gilardi K;Daszak P;Olival KJ;O'Rourke T;Murray S;Olson SH;Togami E;Vidal G;Expert Panel;PREDICT Consortium;Mazet JAK;University of Edinburgh Epigroup members those who wish to remain anonymous
• 通讯作者: University of Edinburgh Epigroup members those who wish to remain anonymous

Inactivation of Ebola Virus and SARS-CoV-2 in Cell Culture Supernatants and Cell Pellets by Gamma Irradiation.

• DOI: 10.3390/v15010043
• 发表时间: 2022-12-23
• 期刊: Viruses
• 作者: Boytz R;Seitz S;Gaudiano E;Patten JJ;Keiser PT;Connor JH;Sharpe AH;Davey RA
• 通讯作者: Davey RA

Recent advances in marburgvirus research.

• DOI: 10.12688/f1000research.17573.1
• 发表时间: 2019-01-01
• 期刊: F1000Research
• 作者: Olejnik, Judith;Muhlberger, Elke;Hume, Adam J
• 通讯作者: Hume, Adam J

Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection.

• DOI: 10.3389/fimmu.2021.614676
• 发表时间: 2021
• 期刊: Frontiers in immunology
• 影响因子: 7.3
• 作者: Yuen RR;Steiner D;Pihl RMF;Chavez E;Olson A;Smith EL;Baird LA;Korkmaz F;Urick P;Sagar M;Berrigan JL;Gummuluru S;Corley RB;Quillen K;Belkina AC;Mostoslavsky G;Rifkin IR;Kataria Y;Cappione AJ 3rd;Gao W;Lin NH;Bhadelia N;Snyder-Cappione JE
• 通讯作者: Snyder-Cappione JE

Previremic Identification of Ebola or Marburg Virus Infection Using Integrated Host-Transcriptome and Viral Genome Detection.

使用整合的宿主转录组和病毒基因组检测对埃博拉或马尔堡病毒感染进行病毒感染前鉴定。

• DOI: 10.1128/mbio.01157-20
• 发表时间: 2020
• 期刊: mBio
• 影响因子: 6.4
• 作者: Speranza,Emily;Caballero,Ignacio;Honko,AnnaN;Johnson,JoshuaC;Bohannon,JKyle;EvansDeWald,Lisa;Gerhardt,DawnM;Sword,Jennifer;Hensley,LisaE;Bennett,RichardS;Connor,JohnH
• 通讯作者: Connor,JohnH